Centene reported Q3 premium and service revenue of $36.9 billion and adjusted diluted EPS of $1.62, while reaffirming 2024 EPS guidance of greater than $6.80 and lifting full-year premium/service revenue guidance by $2 billion. Management said Medicaid membership stabilized near 13 million, Medicaid HBR should peak in Q3 at 93.1%, and 2025 Medicare Advantage revenue is targeted at $14 billion to $16 billion despite portfolio exits. The company also bought back $1.6 billion of stock in Q3 and October, but cash flow was negative $1 billion due to timing of Medicaid and marketplace receipts.
CNC’s real setup is less about the beat and more about the slope change in loss trends. The key second-order effect is that Medicaid redetermination pressure is now transitioning from an adverse selection problem into a normalization story: as rejoiners slow and rate actions catch up to acuity, the company can lap the worst mix distortion into 2025. That matters because it gives management a cleaner path to margin repair without relying on heroic cost cuts, which should support multiple expansion if investors start to believe the 2025 HBR inflection is durable.
The more interesting competitive dynamic is in Medicare and Part D. By exiting weaker Medicare Advantage geographies and shrinking H contracts, Centene is deliberately giving up revenue to improve quality economics and Stars visibility; that is a classic short-term top-line drag that can look bad on the surface but improves the probability of a cleaner earnings stream in 2026-27. In Part D, the IRA-driven revenue uplift is effectively a pricing reset that should help absorb fixed admin costs, which means the operating leverage in 2025 may be better than consensus expects even if utilization runs a bit hotter.
The market is likely underappreciating how much of the cash flow weakness is timing, not structural deterioration. Negative CFO plus buybacks can alarm investors, but the receivable unwind into Q4 creates a near-term catalyst for a cash conversion rebound, and leverage at 2.9x leaves room for continued repurchases if cash normalizes. The main tail risk is policy: exchange integrity rules and Medicaid program changes can slow market growth, but that is a growth headwind more than an earnings cliff, provided Centene keeps execution and rate advocacy intact.
Contrarian takeaway: the stock may be misread as a high-risk managed-care name when it is increasingly a self-help and rate-recovery story with multiple embedded catalysts over the next 2 quarters. If the company shows even modest sequential improvement in Medicaid HBR into Q4 and a clean Investor Day framework for 2025, the market should reassess CNC from a contested turnaround into a credible 2025 EPS grower.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
